Decentrialz logo
  • HIPAA Compliant
  • ISO 27001 Certified
Find Trials
About UsContact
Become a Volunteer+1 877 705 1914

Status:

COMPLETED

Bonipar for Acute and Chronic Musculoskeletal Pain

Lead Sponsor:

Winston Parris, MD

Conditions:

Chronic Pain

Musculoskeletal Pain

Eligibility:

All Genders

18-80 years

Phase:

PHASE2

Brief Summary

This study is a non-inferiority study comparing efficacy and onset of action between the herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac topical solution ...

Detailed Description

This study is a non-inferiority study comparing efficacy and onset of action between the herbal extracts topical solution, Bonipar, and diclofenac sodium topical solution, diclofenac topical solution ...

Eligibility Criteria

Inclusion

  • INCLUSIONARY CRITERIA:
  • Subject with acute and chronic localized musculoskeletal pain
  • Ages 18 to 80 years
  • Subjects of all races, gender or ethnic groups
  • Female subjects of childbearing age must have a negative pregnancy test Female subjects of childbearing age who are sexually active must agree to use appropriate contraceptive measures for the duration of the study. Medically acceptable contraceptives include: (1) surgical sterilization (such as tubal ligation or hysterectomy), (2) approved hormonal contraceptives (such as birth control pills, patches, implants or injections), (3) barrier methods (such as a condom or diaphragm) used with a spermicide, or (4) an intrauterine device (IUD).
  • Willing to provide written informed consent
  • Patients taking opioid or NSAID for their musculoskeletal pain may be included if pain is inadequately controlled
  • EXCLUSIONARY CRITERIA:
  • Patients meeting any of the following criteria will be excluded from the study: Use within 3 days of any topical agents on the affected area
  • Subject with active skin lesions or skin disease or with cutaneous manifestations of systemic illnesses
  • Subject with history of uncontrolled diabetes (A1C of more than 9)
  • Subject with history of uncontrolled hypertension (SBP \> 160 and DBP \> 95)
  • Subject with active uncontrolled GERD (defined as more than 2 episodes per week) or history of peptic ulcer disease
  • Subject with active cancer, spinal cord lesions or spine surgery
  • Subject with allergies to diclofenac or to other non-steroid anti-inflammatory drugs (NSAID)
  • Known allergies to any oils, methyl salicylate and/or camphor
  • Subject is pregnant or lactating
  • Subject with history of heart attack, stroke or blood clot, or recent coronary artery bypass graft surgery (CABG) (i.e., within the last six months)
  • Subject with history of alcohol or drug abuse within 1 year
  • Subject with history of severe cardiac, liver or kidney disease or any other medical condition that may interfere with the subject's ability to participate in the study as determined by the Investigator

Exclusion

    Key Trial Info

    Start Date :

    December 15 2020

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    September 22 2022

    Estimated Enrollment :

    164 Patients enrolled

    Trial Details

    Trial ID

    NCT03471507

    Start Date

    December 15 2020

    End Date

    September 22 2022

    Last Update

    September 18 2023

    Active Locations (1)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (1 locations)

    1

    Duke University Medical Center

    Durham, North Carolina, United States, 27710